期刊文献+

循环miR-375作为2型糖尿病生物标志物的研究进展 被引量:6

Research progress of miR-375 used as a new biomarker for type 2 diabetes mellitus
原文传递
导出
摘要 MicroRNAs(miRNAs)是微小非编码RNA,控制基因表达、参与生理病理过程,很多miRNAs主动或被动释放到循环系统中,可用于评价健康状态和疾病进程,是新生物标志物的候选者。miR-375是人和小鼠胰岛中表达量最高的一个miRNA,可作为胰岛特异的标志物,也是糖尿病潜在的新生物标志物。本文对循环miR-375作为T2DM新生物标志物的研究进展和存在问题作简要综述。 MicroRNAs (miRNAs) are small noncoding RNAs,which control gene expression and participate in many physiopathological processes. Hundreds of miRNAs actively or passively released into the circulation can be used to evaluate health status and disease progression, and be potential candidate of new biomarkers, miR-375 is highly expressed in human and rodent islets and used as specific marker of islets and potential new biomarker for diabetes mellitus. This paper reviews the research progress and exiting problems of miR-375 as a new biomarker for type 2 diabetes mellitus.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2016年第11期1029-1031,共3页 Chinese Journal of Diabetes
基金 国家自然科学基金(81471001)
关键词 MICRORNA miR-375 生物标志物 糖尿病 2型 循环 MicroRNA (miRNA) miR-375 Biomarkers Diabetes mellitus, type 2 Circulation
  • 相关文献

参考文献12

  • 1范月蕾,陈大明,于建荣.生物标志物研究进展与应用趋势[J].生命的化学,2013,33(3):344-351. 被引量:8
  • 2Biomarkers Definitions Working Group. Biomarkers andsurro- gate endpoints: preferred definitions and conceptualframework. Clin Pharmacol Ther; 2001,69 .. 89-95. 被引量:1
  • 3Guay C, Regazzi R. Circulating microRNAs as novel biomark- ers for diabetes rnellitus. Nat Rev Endoerinol, 2013,9: 513-521. 被引量:1
  • 4Li X. MiR-375, a mieroRNA related to diabetes. Gene, 2014, 533 : 1-4. 被引量:1
  • 5Weber JA,Baxter DH,Zhang S, et aL The microRNA spectrum in 12 body fluids. Clin Chern, 2010,56 : 1733-1741. 被引量:1
  • 6Poy MN, Hausser J,Trajkovski M, et al. miR-375 maintains nor- malpancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A, 2009,106-5813-5818. 被引量:1
  • 7ZampetakiA, Kieehl S, Drozdov I, et al. Plasma microRNA pro- filing reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. (=ire Res, 2010,107 810-817. 被引量:1
  • 8Kong L,Zhu J,Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol, 2011,48: 61-69. 被引量:1
  • 9Karolina I,Tavintharan S,Armuqarn A,et al. Circulating miR.NA profiles in patients with metabolic syndrome J Clin Endinol Metab, 2012,97: E2271-E2276. 被引量:1
  • 10Latreille M, Herrmanns K, Renwick N, et al. miR-375 gene dosage in pancreatic -cells: implications for regulation of l]-cell mass and biomarker development. J Mol Med ( Bed), 2015,93 : 1159-1169. 被引量:1

二级参考文献19

  • 1Biomarkers Definitions Working Group. Atkinson AJColbum WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 2001, 69:89-95. 被引量:1
  • 2Rundle A, Ahsan H, Vineis P. Better cancer biomarker discovery through better study design. Eur J Clin Invest, 2012, 42:1350-1359. 被引量:1
  • 3Ratain M J, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res, 2007, 13:6545-6548. 被引量:1
  • 4Critical Path 2010 Update. http://www.fda.gov/ ScienceResearch/SpecialTopics/CriticalPathInitiative/ ucm204289.htm [2011-7-4]. 被引量:1
  • 5The European Medicines Agency Road Map to 2015 the Agency's Contribution to Science, Medicines,health http://www.emea.europa.eu/docs/en GB/document_ library/Report/2010/01/WC500067952.pdf [2010-1-26]. 被引量:1
  • 6Policy lssues for the Development and Use of Biomarkers in Health. http://www.oecd.org/sti/biotechnologypolicies/ 49023036.pdf. 被引量:1
  • 7Innovation or stagnation: challenge and opportunity on the critical path to new medical products, http://www.fda. gov/ScienceResearch/SpecialTopics/CriticalPathlnifiative/ CriticalPathOpportunitiesReports/ucm077262.htm [2004-3-16]. 被引量:1
  • 8Predictive Safety Testing Consortium (PSTC). http:// www.fda.gov/AboutFDA/PartnershipsCollaborations/ PublicPrivatePartnershipProgram/ucm231132.htm [2011 - 7-4]. 被引量:1
  • 9Biomarkers - boon or bane for researchers? http:// careers.covance.com/micro/biomarkers/pdf/boonorbane. pdf [2008-10-7]. 被引量:1
  • 10Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration, AAPS J, 2007, 9:E105-E108. 被引量:1

共引文献7

同被引文献47

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部